Feature | July 09, 2013

New Correlation for Increased Mortality Associated with Transcatheter Valve Replacement

July 9, 2013 — Researchers have announced the results of a clinical study that shows a key difference in the patient’s baseline heart size and function following transcatheter valve replacement (TAVR) that may help predict their medical outcomes. Previous work by these researchers showed that even mild paravalvular aortic regurgitation (PAR), detected by echocardiograms performed on these patients, appears to correlate with increased mortality. The current study revealed that certain baseline characteristics found on the echocardiograms could help predict which patients were more likely to have PAR.

“This is an exciting discovery that will help us better stratify patients for closer follow-up care,” said Rebecca Hahn, M.D., FASE, the study’s primary investigator. Hahn and her colleagues analyzed 465 patients from the PARTNER trial, combined with another 1,757 patients to show the association between increased PAR and the significant difference in baseline echo parameters. The patients’ echocardiograms indicated larger ventricular volumes and mass, lower ejection fractions and more regurgitant valvular disease, all of which appear to be harbingers of underlying issues that influenced the patient’s long-term outcome following the procedure.

Researchers on the study, "Differences in Baseline Echo Parameters in Patients with Varying Severity of Paravalvular Regurgitation Following Transcatheter Valve Replacement," included Rebecca Hahn, Susheel Kodali, Mathew Williams, Tom McAndrew and Martin Leon from Columbia University, New York, N.Y.; Pamela S. Douglas from Duke University Medical Center, Durham, N.C.;  Philippe Pibarot from Laval University, Quebec, QC, Canada; William Stewart from the Cleveland Clinic Foundation, Cleveland, Ohio; and Neil Weissman from Medstar Health Research Institute, Washington, D.C.

For more information: www.asecho.org

Related Content

TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
GE Healthcare, Vivid iq portable cardiovascular ultrasound, RSNA 2016, launch
Technology | Cardiovascular Ultrasound| September 22, 2016
September 22, 2016 — GE Healthcare announced the global commercial launch of its new generation of high-end portable
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Overlay Init